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ReviewA Systematic Review of Treatments of
Relapsed/Refractory Mantle Cell Lymphoma
Madeliene Parrott,1 Simon Rule,2 Michael Kelleher,3 Jayne Wilson4
Abstract
A systematic review was conducted to evaluate the clinical effectiveness and safety of treatments for patients with
relapsed/refractory mantle cell lymphoma (MCL) unsuitable for intensive treatment. The criteria for inclusion of the
trials were established before the review. A search of Medline, Embase, and the Cochrane library databases was
conducted to identify phase II or III randomized controlled trials (RCTs), reported from January 1, 1994 to May 29,
2016. Relevant conference abstracts, citation lists from the included articles, published guidelines, and on-going
clinical trial databases were also searched. Studies were included if they had evaluated any single agent or combi-
nation of treatments for adult patients with relapsed/refractory MCL who had received  1 previous line of therapy.
Seven RCTs were identiﬁed. Only 1 treatment appeared in > 1 trial; therefore, the results from each trial could not be
quantitatively pooled for meta-analysis. The lack of common comparators, differences in baseline characteristics and
inclusion and exclusion criteria, and variances in the response criteria used to measure outcomes made comparison of
the results difﬁcult. Although the direction of effect for progression-free survival (PFS) and overall survival (OS) was in
favor of the experimental drug in all trials, the difference in PFS was statistically signiﬁcant in 5 and OS in 2. None
showed statistical signiﬁcance for both. A noticeable lack of RCTs evaluating treatments for patients with relapsed/
refractory MCL made meaningful comparisons of effectiveness across trials rather difﬁcult. This trend continues,
because all, bar 1, of the 85 ongoing trials in this area are single-arm studies. RCTs are required to enable better
evaluation of the optimal treatment regimen for this group of patients.
Clinical Lymphoma, Myeloma & Leukemia, Vol. 18, No. 1, 13-25ª 2017 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: B-cell lymphoma, MCL, Non-Hodgkin lymphoma, Randomized controlled trials, Systematic published data review
Introduction cyclin D1 and cell cycle dysregulation.7 MCL has 2 main variants.
Mantle cell lymphoma (MCL) is a rare B-cell malignancy
belonging to the non-Hodgkin lymphoma (NHL) group of dis-
eases.1 MCL represents 3% to 10% of all newly diagnosed NHL
cases,2,3 with an incidence of approximately 1 per 100,000 persons
in Europe4 and the United States.5 MCL more commonly affects
men, with a median age at presentation of 65 years2 and is typically
at an advanced stage at diagnosis, Ann Arbor stage III and IV.6
The hallmark of MCL is the chromosomal translocation
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https://doi.org/10.1016/j.clml.2017.10.004Classic MCL is the more common form2 and has an overall survival
(OS) of approximately 4.5 years. The blastoid variant of MCL is rarer
but has been associated with a more aggressive clinical course and
poorer prognosis, with an OS of approximately 15 months.8
MCL frequently has an aggressive clinical course. Although initial
therapy can achieve high overall response rates (ORRs) of 60% to
97%,9 these tend to be short lived, and most patients will eventually
develop relapse and die of their disease. Some patients, however,
have a more indolent form of MCL. Although it is difﬁcult to
identify this group, some markers (eg, SOX11 negativity) might
help to distinguish this indolent form from a more aggressive
phenotype. Ongoing research in the United Kingdom10 aims to
characterize the differences in a prospective trial. Some clinicians
have now adopted a “watch and wait” management approach with
these patients if they are asymptomatic.4
The ﬁrst-line treatment options will depend on the age and
ﬁtness of the patient. Intensive frontline cytarabine-based treat-
ments are reserved for younger, ﬁtter patients because of
their associated toxicity and are commonly consolidated with
autologous transplantation.2,4,7 However, most patients are older orClinical Lymphoma, Myeloma & Leukemia January 2018 - 13
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Systematic Review of Treatments of Relapsed/Refractory MCLmore frail at presentation; thus, this approach is not feasible. A
number of immunochemotherapy options are available for this
group of patients,4 including B-R (bendamustine, rituximab),
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,
prednisolone), VR-CAP (bortezomib, rituximab,Clinical Lymphoma, Myeloma & Leukemia January 2018cyclophosphamide, doxorubicin, prednisone) regimens, with
response rates ranging from 60% to 95% and a median progression-
free survival (PFS) of  5 years. Rituximab maintenance also plays a
role in sustaining the response after R-CHOP induction.11 For the
more frail patients who are unsuitable for immunochemotherapy,
Madeliene Parrott et alless intensive therapies have been recommended, including chlor-
ambucil, bendamustine, or cladribine, usually given in combination
with rituximab,2,7,12 and the R-CVP regimen (rituximab, vincris-
tine, cyclophosphamide, prednisolone).2
No consensus has yet been reached regarding the optimal stan-
dard of care for relapsed/refractory (R/R) disease. Experts have
recommended an alternative immunochemotherapy regimen from
that which was used initially,6 and the selection of treatment will
depend on a number of factors, including the presence of comor-
bidities, patient ﬁtness, and patient wishes. Because many patients
are not suitable for an intensive treatment approach, several options
for the R/R setting have been recommended in the guidelines for
older patients.2,4,13 In the present systematic review, we, therefore,
evaluated the available evidence for therapeutic options for patients
with R/R MCL unsuitable for an intensive treatment approach.
Materials and Methods
The review method was predeﬁned in a protocol available in the
Supplemental Data section (available in the online version) and
registered in the Prospero website (available at: https://www.crd.
york.ac.uk/PROSPERO/). Randomized controlled trials (RCTs)
were included if they met the following criteria: (1) study popula-
tion, adult patients with R/R MCL who had received  1 previous
line of therapy and not eligible for intensive treatment or trans-
plantation; (2) intervention, any single agent or combination of
agents, including chemotherapy, immunotherapy, immunochemo-
therapy, targeted agents, excluding intensive treatment and trans-
plantation; (3) comparator, any single agent or agents, as stated; and
(4) outcomes, OS, PFS, ORR, and safety. Electronic searches were
undertaken in Medline, Embase, and the Cochrane Library from
January 1994 (MCL was accepted as a separate entity in 199414) to
May 29, 2016. In addition, conference proceedings from the annual
congresses of the American Society of Hematology (ASH), Euro-
pean Hematology Association, American Society of Clinical
Oncology, and European Society of Medical Oncology were
searched for the preceding 5 years to ﬁnd unpublished trials.
Citation lists from the included studies, review articles, and pub-
lished guidelines from the National Comprehensive Cancer
Network, European Society of Medical Oncology, ASH, British
Society of Haematology, and European Mantle Cell Lymphoma
Network were also searched. Ongoing trials were identiﬁed from 2
research databases (available at: www.clinicaltrials.gov and www.
clinicaltrialregister.eu) up to December 24, 2016.
The search terms for the population included “lymphoma, mantle-
cell lymphoma, non-Hodgkin lymphoma, B-cell lymphoma” for the
intervention. The control search terms included “drug therapy
[MeSH] OR immunotherapy [MeSH] OR molecular targeted
therapy [MeSH] OR biological therapy [MeSH] OR combined
modality therapy [MeSH] OR antineoplastic agents [MeSH] OR
lenalidomide OR ibrutinib OR thalidomide OR bortezomib OR
temsirolimus OR everolimus OR BTK [Bruton’s tyrosine kinase]
inhibitor OR proteasome inhibitor.” Full details of the search stra-
tegies used are shown in Supplemental Tables 1 and 2 (available in
the online version). No language restrictions were used in the search.
Two reviewers (M.P. and M.K.) independently screened the
search results for potential inclusion and exclusion using the title
and abstract, with full paper copies obtained to conﬁrm inclusion inthe review. The ﬁnal decision for the inclusion of articles was
determined by agreement between the 2 reviewers.
Results
A total of 1746 articles were identiﬁed from the search as out-
lined in the PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) diagram (Figure 1). After 430 dupli-
cates were removed, 1316 articles were initially screened for inclu-
sion from the title and abstract, with 27 published articles retrieved
for full text screening. Seven RCTs met the inclusion criteria and
were included in the present review.15-21 Full agreement had been
reached between the 2 reviewers regarding the included articles. The
concordance between reviewers resulted from both the clearly
deﬁned criteria and the paucity of trials available in this setting.
A summary of the trial design for the included trials is provided
in Table 1, with the treatment regimens for each trial listed in
Table 2. The follow-up duration among the trials varied, with the
shortest median follow-up of 15.9 months in the trial conducted by
Trneny et al21 and the longest median follow-up of 96 months
reported by Rummel et al.20 All 3 trials that had included a variety
of NHL subtypes16,17,20 reported separate outcomes for the MCL
subpopulation and were included in the present review. Only 1
treatment, temsirolimus, appeared in > 1 trial.
Data were extracted from the articles by 1 reviewer (M.P.) and
were checked by a second reviewer (M.K.). The study and patient
characteristics and the details of the intervention and control were
extracted. The outcomes data collected included OS, PFS, tumor
responses, and data on safety, restricted to grade 3 and 4 hemato-
logic toxicity.
Only a descriptive analysis of the included trials was feasible
owing to the heterogeneity of the study populations and
interventions.
Quality Assessment of Studies
The quality of each trial was evaluated using the Cochrane
Collaboration’s tool for assessing the risk of bias.22 Assessment of
the blinding of participants and personnel was not applicable,
because all trials were open label and were therefore listed as unclear
owing to the restrictions of choice within the tool. A full assessment
of each trial is given in Supplemental Table 3 (available in the online
version). Overall, 2 trials15,21 were judged to have a low risk of bias
across all domains, 5 trials16-20 provided insufﬁcient information on
which to judge bias in some domains, and 2 trials18,20 were judged
to have some elements of a high risk of bias (some trials were in > 1
category). The study by Rummel et al20 was judged to have
detection bias because it had not reported the response criteria. The
study by Furtado et al18 was judged to have selection and reporting
bias because of differences in the baseline characteristics between the
2 groups and because they did not report prespeciﬁed outcomes.
A summary of the risk of bias is shown in Figure 2.
Baseline Characteristics
The inclusion criteria were broadly similar among the trials, with
a couple of notable differences. Hess et al19 required patients to have
received  2 previous therapies, the remaining trials only required
1. All trials, where stated, included patients with an Eastern
Cooperative Oncology Group (ECOG) performance status (PS)Clinical Lymphoma, Myeloma & Leukemia January 2018 - 15
Table 1 Trial Design of Included Studies
Investigator Design
Treatment MCL Patients (n)
Inclusion CriteriaID Control ID Control
Dreyling et al,15 2016 Phase III, multicenter, open label,
randomized 1:1, ITT, IWG 2007
Ibrutinib Tems 139 141 R/R MCL, 1 previous rituximab-containing
therapy, ECOG PS 0-1
Forstpointner et al,16
2004
Phase III, multicenter, open label,
randomized 1:1, ITT, IWG 1999
R-FCM FCM 24 26 R/R MCL (35%), FL (49%), lymphoplasmacytic
(11%), other (5%); 1 previous chemotherapy,
including HSCT; PS not stated
Forstpointner et al,17
2006
Phase III, multicenter, open label,
randomized 1:1, ITT, IWG 1999
Rituximab
maintenance
No Tx 24 26 R/R MCL, FL; patients achieving CR or PR on
induction R-FCM; PS not stated
Furtado et al,18 2014 Phase II, multicenter, open label,
randomized 1:1, ITT, IWG 2007
V-CHOP CHOP 23 23 R/R MCL, 1 previous therapy, ECOG PS 2
Hess et al,19 2009 Phase III, multicenter, open label,
randomized 1:1:1, ITT, IWG 2007
Tems HD vs.
LD
ICa HD 54;
LD 54
53 R/R MCL, 2-7 previous therapies, must have
included an alkylating agent, an anthracycline,
and rituximab; ECOG PS 2
Rummel et al,20 2016 Phase III, multicenter, open label,
randomized 1:1, per protocol
analyses; response criteria
not stated
B-R F-R 24 23 R/R MCL (21%), FL (51%), MZL (8%),
WM (11%), unclassiﬁed (9%), 1 previous
therapy, WHO PS 0-2
Trneny et al,21 2016 Phase II, multicenter, open label,
randomized 2:1, ITT, IWG 2007
Lenalidomide ICa 170 84 R/R MCL, 1 previous combination
chemotherapy with an alkylating agent
plus 1 of anthracycline, cytarabine, or
ﬂudarabine with or without rituximab;
ECOG PS 0-2
Abbreviations: B-R ¼ bendamustine, rituximab; CHOP ¼ cyclophosphamide, doxorubicin, vincristine, prednisolone; CR ¼ complete response; ECOG ¼ Eastern Cooperative Oncology Group; FCM ¼
ﬂudarabine, cyclophosphamide, mitoxantrone; FL ¼ follicular lymphoma; F-R ¼ ﬂudarabine, rituximab; HSCT ¼ hematopoietic stem cell transplantation; IC ¼ investigator’s choice chemotherapy;
ID ¼ investigational drug; ITT ¼ intention-to-treat (analyses); IWG 1999 ¼ international working group response criteria 1999; IWG 2007 ¼ IWG revised response criteria 2007; MCL ¼ mantle cell
lymphoma; MZL ¼ marginal zone lymphoma; PR ¼ partial response; PS ¼ performance status; R-FCM ¼ rituximab, ﬂudarabine, cyclophosphamide, mitoxantrone; R/R ¼ relapsed or refractory
disease; Tems ¼ temsirolimus; Tx ¼ treatment; V-CHOP ¼ bortezomib plus CHOP; WHO ¼ World Health Organization; WM ¼ Waldenström’s macroglobulinemia.
aRates of 2-3 previous therapies versus 4-7 previous therapies.
Systematic Review of Treatments of Relapsed/Refractory MCL
16 -of  2. Dreyling et al15 restricted this to an ECOG PS of 1. The
median age of the included patients was similar across the trials,
with median age of 67 to 70 years in most trials.
The baseline characteristics are summarized in Table 3 and were
generally well balanced between the treatment arms in most trials.
Three trials18,19,21 reported an imbalance in some baseline charac-
teristics. In 1 study,19 the treatment groups differed with respect to
blastoid variant, the median number of previous lines of treatment,
and the use of previous bortezomib therapy. Another study18
differed with respect to the proportion of male patients, interval
since diagnosis, and previous rituximab. The third study differed
with respect to tumour burden, bulky disease, lactate dehydrogenase
levels, number of previous therapies, and number of patients with
refractory disease.21
Effectiveness of Treatments
The PFS, OS, and ORRs reported for MCL patients in the
included trials are summarized in Table 4. All the trials reported an
improvement in PFS with the experimental drug, with the differ-
ence statistically signiﬁcant in all, except for 2 of the trials.16,18 All
the trials reported an improvement in OS in favor of the experi-
mental arm, although not all the trials were powered to demonstrate
a statistically signiﬁcant difference in OS between the 2 groups.
Dreyling et al15 compared the oral BTK inhibitor, ibrutinib, to
the intravenous mTOR pathway inhibitor, temsirolimus, in patients
who had received  1 previous rituximab-containing therapy. With
a median follow-up period of 20 months, PFS was signiﬁcantly
improved with ibrutinib compared with temsirolimus (hazard ratio
[HR], 0.43; 95% conﬁdence interval [CI], 0.32-0.58; P < .0001),Clinical Lymphoma, Myeloma & Leukemia January 2018with a median PFS with ibrutinib of 14.6 months versus 6.2
months with temsirolimus. The relative reduction in the risk of
death in patients receiving ibrutinib compared with temsirolimus
was 24% (HR, 0.76; 95% CI, 0.53-1.09; P ¼ .1324). The median
OS was not reached in the ibrutinib arm compared with 21.3
months in the temsirolimus arm. 23% of the patients receiving
temsirolimus crossed over to the ibrutinib arm. The ORR as
assessed by independent review was signiﬁcantly greater for ibruti-
nib than for temsirolimus (72% vs. 40%; P < .0001). Additionally,
the complete response (CR) rates were superior (19% with ibrutinib
vs. 1% with temsirolimus; odds ratio, 3.98; 95% CI, 2.38-6.65). At
18 months, the estimated rate of response was 58% (range, 46%-
68%) for ibrutinib compared with 20% (range, 9%-35%) for
temsirolimus.
Hess et al19 compared 2 intravenous temsirolimus regimens (175
mg weekly for 3 weeks, followed by either 75 mg weekly or 25 mg
weekly) and investigator’s choice (IC) chemotherapy for patients
who had received 2 to 7 previous therapies, which must have
included an alkylating agent, an anthracycline, and rituximab. The
improvement in PFS was statistically signiﬁcant with the higher
dose temsirolimus compared with the IC cohort (HR, 0.44; 97.5%
CI, 0.25-0.78; P ¼ .0009). A nonsigniﬁcant improvement in PFS
was noted with the lower dose of temsirolimus (HR, 0.65; 97.5%
CI, 0.39-1.10; P ¼ .062). A longer median PFS was observed in the
high-dose cohort compared with the IC (4.8 vs. 1.9 months) and
the low-dose cohort (3.4 vs. 1.9 months with IC). Higher dose
temsirolimus resulted in a 20% relative reduction in the risk
of death compared with IC chemotherapy (HR, 0.80; 95% CI,
0.50-1.28; P ¼ .35), but the difference did not reach statistical
Table 2 Regimens Used in Trials Listed in Table 1
Drug Dosage and Schedule
Ibrutinib Oral 560 mg daily until progression
Temsirolimus IV temsirolimus 175 mg on days 1, 8, 15 of cycle 1,
followed by 75 mg on days 1, 8, 15 of subsequent
21-d cycles until progression or unacceptable toxicity
FCM IV ﬂudarabine 25 mg/m2 on days 1-3 plus IV
cyclophosphamide 200 mg/m2 on days 1-3 plus IV
mitoxantrone 8 mg/m2 on day 1 for 4 cycles
R-FCM IV rituximab 375 mg/m2 on day 0 plus FCM as before
for 4 cycles
Rituximab
maintenance
2 Courses of IV rituximab 3 and 9 mo after completion
of induction; each course: 4 doses of IV rituximab
375 mg/m2 for 4 consecutive weeks
CHOP IV cyclophosphamide 750 mg/m2 plus IV doxorubicin
50 mg/m2 plus IV vincristine 1.4 m/m2 to maximum
of 2 mg on day 1 of each cycle plus oral prednisolone
100 mg/d for maximum of 8 cycles
V-CHOP IV bortezomib 1.6 mg/m2 on days 1 and 8 of 21-d cycle
plus CHOP as before for maximum of 8 cycles
Temsirolimus HD IV temsirolimus as before until progression or
unacceptable toxicity
Temsirolimus LD IV temsirolimus 175 mg on days 1, 8, and 15 of
cycle 1, followed by 25 mg on days 1, 8, and 15 of
subsequent 21-d cycles until progression or
unacceptable toxicity
B-R IV bendamustine 90 mg/m2 on days 1 and 2 plus IV
rituximab 375 mg/m2 on day 1 every 4 wk for maximum
of 6 cycles
F-R IV ﬂudarabine 25 mg/m2 on days 1-3 plus rituximab as
before for maximum of 6 cycles
Lenalidomide Oral lenalidomide 25 mg on days 1-21 of 28-d cycle until
progression or unacceptable toxicity
ICa IV gemcitabine 1000 mg/m2 on days 1, 8, and 15
every 28 d for maximum of 6 cycles OR IV ﬂudarabine
25 mg/m2 or oral ﬂudarabine 40 mg/m2 on days 1-5
every 28 d for maximum of 6 cycles OR oral chlorambucil
0.1-0.2 mg/kg daily for 3-6 wk OR IV cladribine 5 mg/m2
daily for 5 d every 28 d OR IV etoposide 50-150 mg/m2
daily for 3-5 d every 21-28 d OR oral thalidomide
200 mg daily OR IV vinblastine 10 mg weekly OR IV
alemtuzumab 30 mg/d 3 times weekly OR oral
lenalidomide 25 mg daily for 28 d
ICb IV rituximab 375 mg/m2 on days 1, 8, 15, and 22
and then once every 56 d until progression OR IV
gemcitabine as before OR either ﬂudarabine as before
OR IV chlorambucil 40 mg/m2 monthly divided over
days 3-10 until progression OR IV cytarabine 1-2 g/m2
on days 1 and 2 every 28 d for maximum of 6 cycles
Abbreviations: B-R ¼ bendamustine, rituximab; CHOP ¼ cyclophosphamide, doxorubicin,
vincristine, prednisolone; FCM ¼ ﬂudarabine, cyclophosphamide, mitoxantrone; F-R ¼ ﬂudar-
abine, rituximab; HD ¼ high dose; IC ¼ investigator’s choice; IV ¼ intravenous; LD ¼ low dose;
R-FCM ¼ rituximab, ﬂudarabine, cyclophosphamide, mitoxantrone; V-CHOP ¼ bortezomib plus
CHOP.
aInvestigator’s choice in Hess et al trial.
bInvestigator’s choice in Trneny et al trial.
Madeliene Parrott et alsigniﬁcance. The lower dose achieved a 4% relative reduction in the
risk of death compared with the IC (HR, 0.96; 95% CI, 0.60-1.54;
P ¼ .87). The ﬁnal median OS analysis demonstrated an
improvement in favor of the higher dose of temsirolimus compared
with the IC (12.8 vs. 9.7 months; P ¼ .35). The median OS
observed with the lower dose cohort was 10 months (P ¼ .87).
High-dose temsirolimus resulted in superior ORR compared with
IC chemotherapy (22% vs. 2%; P ¼ .0019). The ORR with low-dose temsirolimus was 6% (P ¼ .61). The CR rate with high-
dose temsirolimus was comparable to that of the IC (2% vs. 2%),
although the partial response (PR) rate was improved (20% vs. 0%).
The use of R-FCM (the addition of rituximab [an anti-CD20
monoclonal antibody] to FCM [ﬂudarabine, cyclophosphamide,
mitoxantrone]) chemotherapy was compared with FCM alone by
Forstpointner et al16 in a mixed population of lymphoma subtypes
(49% had follicular lymphoma (FL), 35% had MCL, and 11% had
lymphoplasmacytic/cytoid lymphoma) who had received  1 pre-
vious line of treatment. The trial was stopped early with 128 pa-
tients recruited owing to the signiﬁcant advantage observed in favor
of R-FCM. PFS was signiﬁcantly improved with R-FCM compared
with FCM alone in the overall population (median PFS, 16 vs. 10
months; P ¼ .038) after a median follow-up of 18 months. In an
exploratory analysis of the histologic subgroups, a shorter median
PFS was observed for the MCL population compared with the total
population (R-FCM, 8 vs. 4 months with FCM; P ¼ .389). The
investigators used a second randomization17 to maintenance ritux-
imab or no maintenance for patients who had achieved a CR or PR.
Although the median duration of response for MCL patients was
similar in both arms (14 months with maintenance vs. 12 months
without maintenance; P ¼ .049), a greater proportion of MCL
patients receiving maintenance rituximab experienced ongoing
remission > 2 years (45% vs. 9%). A statistically signiﬁcant beneﬁt
in median OS was observed in the cohort of MCL patients receiving
R-FCM compared with FCM (OS, not reached vs. 11 months
[estimated]; P ¼ .0042). These patients represented 35% of the
total population. In addition, at 2 years, 65% of the MCL patients
receiving R-FCM were still alive compared with 35% of patients
treated with FCM. R-FCM resulted in an improved ORR
compared with FCM alone (58% vs. 46%; P ¼ .282). More MCL
patients experienced a CR with R-FCM than with FCM (29% vs.
0%), although more patients in the FCM arm achieved a PR (29%
vs. 46%).
Furtado et al18 compared V-CHOP (bortezomib [an inhibitor of
the 26S proteasome], cyclophosphamide, doxorubicin, vincristine,
prednisolone) for a maximum of 8 cycles to CHOP in MCL pa-
tients who had been treated with  1 previous line of therapy. The
phase II trial recruited 46 patients and was stopped early by the
independent data monitoring committee owing to the signiﬁcant
differences in OS between the 2 cohorts. After a median follow-up
of 34 months, a nonsigniﬁcant improvement in PFS was observed
with the V-CHOP combination compared with CHOP alone (HR,
0.60; 95% CI, 0.31-1.15; P ¼ .12). The median PFS observed with
the V-CHOP combination was 16.5 months compared with 8.1
months with CHOP, with a signiﬁcant improvement in OS ach-
ieved with V-CHOP (HR, 0.37; 95% CI, 0.16-0.83; P ¼ .01). The
median OS of 35.6 months with V-CHOP was substantially longer
than that observed with CHOP at 11.8 months. The addition of
bortezomib to CHOP resulted in a superior ORR compared with
CHOP alone (82.6% vs. 47.8%; P ¼ .01). A nonsigniﬁcant
improvement in CR rates (34.8% vs. 21.7%; P ¼ .33) and PR rates
(47.8% vs. 26.1%; P ¼ .13) was also noted.
Rummel et al20 compared B-R (bendamustine, rituximab) and F-R
(ﬂudarabine, rituximab) in a mixed cohort of patients who had
received  1 previous therapy. Of their patients, 51% had FL, 21%
had MCL, 11% had Waldenström’s macroglobulinemia, 8% hadClinical Lymphoma, Myeloma & Leukemia January 2018 - 17
Figure 2 Risk of Bias Summary. Assessment of Blinding of
Participants and Personnel Was Not Applicable
Because All Trials Were Open Label. The Trials Were
Listed as Having an Unclear Risk of Bias Owing to the
Restrictions of Choice Within the Bias Tool. Green
Indicates a Low Risk of Bias; Yellow, an Unclear Risk
of Bias; and Red, a High Risk of Bias
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18 -marginal zone lymphoma, 8% had lymphoplasmacytic lymphoma, and
1% had low-grade disease, unclassiﬁed. A maximum of 6 cycles of
either chemotherapy combination was administered to 230 patients.
The protocol was amended during the course of the trial to include
rituximab maintenance therapy for patients who had responded to B-R
or F-R, because maintenance rituximab treatment had been approved
for patients with FL. In patients with MCL, the improvement in PFS
was statistically signiﬁcant in the B-R arm (HR, 0.45; 95% CI, 0.22-
0.76; P ¼ .01), with a median PFS of 17.6 months achieved with B-R
compared with 4.7 months with F-R. An improvement in median OS
was also observed (B-R group, 35.3 months vs. 20.9 months for the F-
R group; P ¼ not reported). The effect of maintenance rituximab was
not reported for the MCL patients. A superior ORR for the MCL
patients receiving B-R was achieved (70.8% vs. 26.1%). Both the CR
rate (37.5% vs. 13%) and the PR rate (33.3% vs. 13%) were sub-
stantially greater for the MCL patients treated with B-R compared with
those treated with F-R.
Trneny et al21 compared oral lenalidomide to IC single-agent
chemotherapy in 254 MCL patients. The patients had to have
received  1 combination chemotherapy regimen comprising anClinical Lymphoma, Myeloma & Leukemia January 2018alkylating agent and  1 of an anthracycline, cytarabine, or ﬂudar-
abine, with or without rituximab. After a median follow-up of 15.9
months, the improvement in PFS was statistically signiﬁcant with
lenalidomide (HR, 0.61; 95% CI, 0.44-0.84; P ¼ .004) compared
with IC, with a prolonged median PFS of 8.7 months versus 5.2
months in the IC arm. A signiﬁcant improvement was demonstrated
in favor of lenalidomide compared with most of the individual IC
therapies. A nonstatistically signiﬁcant difference in OS was reported
for patients treated with lenalidomide compared with patients treated
with IC (HR, 0.89; 95% CI, 0.62-1.28; P ¼ .45). The median OS
was 27.9 months with lenalidomide compared with 21.2 months
with IC. The trial was not powered to demonstrate a survival dif-
ference between the 2 arms and was further compounded by patients
crossing over to the lenalidomide arm at disease progression. A sig-
niﬁcant improvement in ORR was observed for patients receiving
lenalidomide compared with IC chemotherapy (40% vs. 11%; P <
.001). The CR rate was 5% with lenalidomide versus 0% (P¼ .043).
The PR rate was 35% versus 11% with IC. The duration of response
was signiﬁcantly prolonged with lenalidomide compared with IC
(16.1 vs. 10.4 months; P ¼ .043).
Safety
A summary of grade  3 hematologic toxicities observed in the
trials is presented in Figure 3. Patients treated with ibrutinib had a
longer duration of treatment exposure compared with the control
arm in the trial by Dreyling et al15 (14.4 vs. 3 months), with a mean
relative dose intensity of 99.9% for ibrutinib versus 81.8% for
temsirolimus. Adverse events caused treatment discontinuation and
dose reductions in 6% and 4% of patients in the ibrutinib arm
compared with 26% and 43% in the comparator group,
respectively.
The median duration of temsirolimus 175/75-mg treatment was
more than double that of IC (12 vs. 5 weeks) in the trial by Hess
et al.19 Signiﬁcantly greater rates of thrombocytopenia and anemia
were observed with temsirolimus. In contrast, leukopenia was more
frequent with IC chemotherapy than with higher dose temsirolimus
(all grades, 15% vs. 40% with IC), as was neutropenia (all grades,
24% vs. 40% with IC). Of the patients in the temsirolimus 175/75-
mg arm, 22% discontinued treatment because of an adverse event
compared with 11% in the IC arm.
The frequency of grade 3/4 hematologic toxicities was compa-
rable across both treatment groups in the trial by Forstpointner
et al,16 except for lymphocytopenia, which was more common
across grades 1 to 4 in the R-FCM arm than in the FCM arm. The
extended use of rituximab during the maintenance phase of the
trial17 did not result in any signiﬁcant differences in the adverse
events between the 2 arms.
Furtado et al18 reported a similar rate of grade  3 thrombocy-
topenia between the 2 arms. However, a signiﬁcant increase in the
rate of grade  3 neutropenia was observed in the experimental arm,
which translated to a greater rate of febrile neutropenia with the V-
CHOP regimen. Non-neutropenic infection rates were also higher;
however, these were primarily low grade.
The B-R and F-R combinations were both well tolerated by
patients in the trial by Rummel et al.20 The dose intensity was
96.3% in the B-R group and 99.5% in the F-R arm, indicating
good tolerability for both regimens.
Table 3 Baseline Characteristics of Trial Population
Investigator
Median Age (y)
Median Time from
Original Diagnosis to
Randomization (mo)
Blastoid vs. Classic
Histologic Type (%)
Low vs. Med vs.
High sMIPI (%)
Relapsed vs.
Refractory (%)
Previous Lines of Therapy
1-2 vs. >2 (%)
ID C ID C ID C ID C ID C ID C
Dreyling et al,15 2016;
Ibr vs. Tems
67 68 38.9 46.23 12 vs. 88 12 vs. 88 32 vs. 47
vs. 22
30 vs. 49
vs. 21
74 vs. 26 67 vs. 33 68 vs. 32 66 vs. 34
Forstpointner et al,16
2004; R-FCM vs. FCM
65 63 24 for total population NS NS NS NS NS NS 83 vs. 17a 84 vs. 17a
Forstpointner et al,17
2006; R-main vs. Obs
63 63 35 for total population NS NS NS NS NS NS 97 vs. 4a 100 vs. 0a
Furtado et al,18 2014;
V-CHOP vs. CHOP
69 71 24.7 19.7 NS NS NS NS NS NS NS
Hess et al,19 2009; Tems
vs. IC
HD, 68;
LD, 68.5
64.5 HD, 49.6;
LD, 47.7
48.5 HD, 0 vs. 85;
LD, 17 vs. 65
7 vs. 74 NS NS NS NS HD 52 vs. 48b;
LD 59 vs. 41b
39 vs. 61b
Rummel et al,20 2016;
B-R vs. F-R
71.6 69.4 NS NS NS NS NS 96 vs. 4 95 vs. 5 79.1 vs. 20.8 87 vs. 13
Trneny et al,21 2016;
L vs. IC
68.5 68.5 54 vs. 45c 52 vs. 46c NS NS 25 vs. 39
vs. 35d
25 vs. 44
vs. 30d
59 vs. 41 70 vs. 30 73 vs. 26 71 vs. 29
Abbreviations: B-R ¼ bendamustine, rituximab; C ¼ control; CHOP ¼ cyclophosphamide, doxorubicin, vincristine, prednisolone; F-R ¼ ﬂudarabine, rituximab; ID ¼ investigational drug; HD ¼ high dose; Ibr ¼ ibrutinib; IC ¼ investigator’s choice; L ¼ lenalidomide; LD ¼ low
dose; NS ¼ not stated; Obs ¼ observation; R-FCM ¼ rituximab, ﬂudarabine, cyclophosphamide, mitoxantrone; R-main ¼ rituximab maintenance; sMIPI ¼ simpliﬁed mantle cell lymphoma international prognostic index; Tems ¼ temsirolimus; V-CHOP ¼ bortezomib,
cyclophosphamide, doxorubicin, vincristine, prednisolone.
aPercentage of 1 previous and 2 previous therapies summed for this group.
bRates of 2-3 previous therapies versus 4-7 previous therapies.
cDuration < 3 y versus > 3 y.
dBoth arms missing data for 2%.
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Table 4 Efﬁcacy Outcomes for MCL Patients in Included Trials
Investigator OA
PFS (mo) OS (mo) ORR (%) CR (%) PR (%)
M
HR
(95% CI) P Value M
HR
(95% CI) P Value ORR
OR
(95% CI) P Value CR
OR
(95% CI) P Value PR
OR
(95% CI)
Dreyling et al,15 2016 ITT 14.6 vs.
6.2
0.43
(0.32-0.58)
<.0001 NRa vs.
21.3
0.76
(0.53-1.09)
.1324 72 vs. 40 NRb .0001 19 vs. 1 3.98
(2.38-6.65)
NRb NRb NRb
Forstpointner et al,16 2004 ITT 8 vs. 4 NRb .3887 NRa vs. 11
(est)
NRb .0042 58 vs. 46 NRb .282 29 vs. 0 NRb NRb 29 vs. 46 NRb
Forstpointner et al,17 2006 Initial R-FCM
therapy
14 vs. 12c NRb .049 45% vs.
9%d
NRb NRb NRb NRb NRb NRb NRb NRb NRb NRb
Furtado et al,18 2014 ITT 16.5 vs. 8.1 0.6
(0.31-1.15)
.12 35.6 vs.
11.8
0.37
(0.16-0.83)
.01 82.6 vs.
47.8
0.14
(0.3-0.62)
.01 34.8 vs.
21.7
0.52
(0.14-1.93)
.33 47.8 vs.
26.1
0.39
(0.11-1.33)
Hess et al,19 2009e ITT 4.8 vs. 1.9 0.44
(0.25-0.78)
.0009 12.8 vs.
9.7
0.80
(0.50-1.28)
.3519 22 vs. 2 NRb .0019 2 vs. 2 NRb NRb 20 vs. 0 NRb
Rummel et al,20 2016 Per protocol 17.6 vs.
4.7
0.45
(0.22-0.76)
.01 35.3 vs.
20.9
NRb NRb 70.8 vs. 26.1 NRb NRb 37.5 vs. 13 NRb NRb 33.3 vs. 13 NRb
Trneny et al,21 2016 ITT 8.7 vs. 5.2 0.61
(0.44-0.84)
.004 27.9 vs.
21.2
0.89
(0.62-1.28)
.45 40 vs. 11 NRb .001 5 vs. 0 NRb NRb 35 vs. 11 NRb
Abbreviations: CI ¼ conﬁdence interval; CR ¼ complete response; est ¼ estimated; HR ¼ hazard ratio; ITT ¼ intent to treat; M ¼ median; OA ¼ outcomes analysis; OR ¼ odds ratio; ORR ¼ overall response rate; PFS ¼ progression-free survival; PR ¼ partial response;
R-FCM ¼ rituximab, ﬂudarabine, cyclophosphamide, mitoxantrone.
aNot reached.
bNot reported.
cMedian response duration.
dOngoing remissions > 2 y.
eResults for higher dose.
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Madeliene Parrott et alDose reductions were more common in the lenalidomide group
(41% vs. 17%),21 but discontinuations were more common in the
IC group (5% vs. 16%). The rates of grade  3 neutropenia were
greater in the lenalidomide arm, with febrile neutropenia reported
in 6% of patients receiving lenalidomide compared with 2% of
patients receiving IC. The rates of anemia were comparable, with
the incidence of thrombocytopenia greater in the IC arm.
Unpublished and Ongoing Trials
The data from 4 trials23-26 were presented at the 58th annual
meeting of the ASH held in San Diego from December 3 to 6, 2016.
All 4 trials had assessed combinations of treatments for R/R
MCL.23-26 All these trials were single-arm studies but give an indi-
cation of emerging potential future management approaches. Jerke-
man et al23 on behalf of the Nordic Lymphoma Group combined
ibrutinib with lenalidomide and rituximab. The investigators reported
that of the 50 patients enrolled to date, 29 were evaluable for response
and had achieved an impressive ORR rate of 83% and CR of 41%,
with the median PFS not reached. Morschhauser et al26 presented the
results on behalf of the LYSA (Lymphoma Study Association) group
from their study combining lenalidomide with obinutuzumab, an
anti-CD20 monoclonal antibody. Seven MCL patients completed
the induction phase and achieved an ORR of 38.5%, with CR in
23.1%, as evaluated using the revised International Working Group
(IWG) 2007 criteria.27 These improved ORR and CR rates would
indicate a deeper response with the combination of therapies, which
might, in time, translate to longer PFS and OS for patients.
As of December 2016, 85 trials were ongoing (www.clinicaltrials.
gov and www.clinicaltrialsregister.eu), aiming to recruit > 2300
patients with relapsed/refractory MCL to evaluate monotherapies
and combinations of agents. Of these 85 trials, 53 are phase I or
phase I/II trials, 26 are in phase II, 1 trial is phase III, and 1 trial is
phase IV. The remaining 4 trials are either retrospective or stated asFigure 3 Grade ‡ 3 Hematologic Toxicities
Ibrut Tems R-FCM FCM Ritux Nomaint
V-
CHOP CHO
Dreyling M,
2016
Forstpointner
R, 2004
Forstpointner
R,  2006
Furtado M
2014
Neutropenia G3+ 13.0 17.0 53.6 55.6 10.0 5.0 30.4 19.
Anaemia G3+ 8.0 20.0 5.9 5.3 3.0 3.0 8.7 13.
Thrombocytopenia G3+ 9.0 42.0 11.7 11.3 4.0 3.0 21.7 21.
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
Abbreviations: B-R ¼ bendamustine, rituximab; CHOP ¼ cyclophosphamide, doxorubicin, vincrist
rituximab; G3þ ¼ grade  3; HD ¼ high dose; Ibrut ¼ ibrutinib; IC ¼ investigator’s choice; Lenal
vincristine, prednisolone; R-FCM ¼ rituximab, ﬂudarabine, cyclophosphamide, mitoxantrone; ritux ¼pilot studies, with no further details. Only the phase III trial is a
RCT (Supplemental Table 4; available in the online version). Of the
remaining 26 ongoing phase II trials, 13 are evaluating combina-
tions of treatments and 13 are assessing monotherapies. Ibrutinib is
included in 5 combination trials, lenalidomide in 3 combination
studies, 1 of which is with bendamustine, and bortezomib is
combined with additional treatments in 2 trials.
Discussion
No consensus has been reached about the standard of care for R/
R MCL and the current UK,2 European Union,4 and US13
guidelines reﬂect this. As demonstrated by the search results,
many reported studies have assessed treatment regimens for this
disease; however, the vast majority have been single-arm, non-
randomized trials that relied on historical controls for comparison.
Bortezomib, ibrutinib, and lenalidomide all received marketing
authorization based on single-arm phase II trials,28-30 which might
have reﬂected the unmet medical need for this group of patients at
the time. The lack of RCTs evaluating treatments for R/R MCL is
noticeable and limited the scope of the present systematic review.
Only 7 RCTs15-21 were identiﬁed for the present review, 6 of which
were distinct trials. Of these, only 2 met all the criteria set out in the
Cochrane’s Collaboration tool for assessing the risk of bias.
Three of the trials had mixed populations. MCL is a rare, but
aggressive, B-cell malignancy that behaves quite differently from
other subtypes of NHL, resulting in distinctive responses to treat-
ment, as demonstrated in the trial by Rummel et al.20 In their trial,
MCL patients receiving the combination of bendamustine and
rituximab achieved a median PFS of 17.6 months. In contrast,
patients with FL achieved a median PFS of 54.5 months with the
same regimen. These were exploratory subgroup analyses; never-
theless, this highlights the need to evaluate treatments for a pure
MCL population to draw clinically meaningful conclusions. It canP Tems(HD) IC B-R F-R Lenalid IC
, Hess G, 2009 Rummel M,2016
Trneny M,
2016
6 15.0 26.0 6.0 4.0 24.0 16.0
0 20.0 17.0 1.0 1.0 7.0 6.0
7 59.0 36.0 2.0 1.0 15.0 19.0
Neutropenia G3+
Anaemia G3+
Thrombocytopenia G3+
ine, prednisolone; FCM ¼ ﬂudarabine, cyclophosphamide, mitoxantrone; F-R ¼ ﬂudarabine,
id ¼ lenalidomide; maint, maintenance; R-CHOP ¼ rituximab, cyclophosphamide, doxorubicin,
rituximab; Tems ¼ temsirolimus.
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22 -be challenging to accrue a sufﬁcient number of patients to a trial
when the disease is rare, and collaborative research groups have been
established because of this. Forstpointner et al16 had only included
48 patients with MCL when further recruitment was halted owing
to the signiﬁcant advantage observed in the R-FCM arm, which had
a mixed population of lymphoma subtypes. The trial by Furtado
et al18 had planned to recruit 90 patients. However, the trial was
stopped early owing to a signiﬁcant difference in survival observed at
the ﬁrst predetermined evaluation point; thus, only 46 patients were
included. Neither trial was statistically designed for such small
numbers; therefore, the statistical signiﬁcance of the results could be
unreliable. The median PFS observed with V-CHOP treatment was
double that with CHOP alone in the trial by Furtado et al,18 yet
this did not achieve statistical signiﬁcance.
It is difﬁcult to make meaningful comparisons of effectiveness
across the included trials in the present review because the inclusion
and exclusion criteria differed among the trials. The trial by Dreyling
et al15 excluded patients with an ECOG PS> 1. The remaining trials
allowed patients with an ECOG PS of 0 to 2.18-21 Most trials
included patients who had received  1 line of previous ther-
apy15,16,18,20,21; however, these previous therapies differed between
the trials and might have had some impact on the outcomes achieved.
Previous rituximab therapy could have introduced an outcome bias to
those trials allowing previous exposure. Rule et al31 demonstrated that
the addition of rituximab to ﬂudarabine-based chemotherapy in pa-
tients with newly diagnosed MCL improved OS, resulting in a
reduction in the hazard of death by 31%. In addition, it has been
suggested that previous bortezomib treatment sensitizes MCL to
subsequent therapies.32 Another baseline factor that could affect the
outcomes include the interval from the initial diagnosis to random-
ization because the longer time might suggest that these patients had
more indolent disease and could safely wait to start therapy. The
proportion of patients with the more difﬁcult to treat blastoid his-
tologic type will also affect the outcomes. The split between patients
with relapsed disease and those with refractory disease will inﬂuence
the outcomes, because refractory disease is generally a harder-to-treat
subtype. Additional factors that should be considered when
comparing trials are the differences in the MCL international prog-
nostic index scores, the proportion of patients with high Ki-67 scores,
indicating more aggressive disease, and other biologic factors such as
TP53 mutation or SOX11 status, which will affect the outcomes.
The ideal would be to have these balanced between the arms of each
trial, and stratiﬁcation before randomization might achieve this.
However, in a rare disease, this can be difﬁcult to achieve in practice.
The blastoid histologic type represents a small proportion of the total
MCL population; it is important that patients with this subtype are
included in trials to collect data on how they respond to various
treatments. It would not be feasible to perform a trial of this subtype
alone; therefore, imbalances in the baseline characteristics of this
nature between treatment arms should be tolerated, acknowledging
that they could affect the results.
The response criteria by which outcomes were measured also
differed among the studies. It is important that consistent deﬁni-
tions of endpoints are used to allow for comparisons among clinical
trials. The 1999 IWG criteria33 were revised in 200727 and
eliminated the need for the response criterion, CR unconﬁrmed,
and incorporated the assessment of extranodal disease. In a trial23Clinical Lymphoma, Myeloma & Leukemia January 2018recently presented at the 58th Annual Meeting of the ASH in
2016, 2 analyses were conducted within the same trial, 1 using the
1999 IWG criteria33 demonstrating an ORR of 46.2% and a CR/
CR unconﬁrmed of 15.4%. The other analysis used the revised
2007 IWG criteria27 and reported an ORR of 38.5% and CR of
23.2%, demonstrating some differences in the response rates ac-
cording to the criteria used. Four of the trials15,18,19,21 in the
present review used the revised 2007 IWG criteria27; however,
both trials by Forstpointner et al16,17 used the 1999 IWG
criteria.33 The revised criteria27 also provide clear deﬁnitions of
time to event outcomes; for example, PFS and OS are measured
from the point of randomization to the date of disease progression
or death from any cause. The deﬁnitions of PFS were inconsistent
among the trials. Three trials15,19,21 used the IWG deﬁnition. Two
trials,16,20 however, used the deﬁnition: “progression-free survival
is the interval between the start of treatment/ﬁrst treatment and
documentation of progressive disease or death from any cause.”
One trial18 did not provide a deﬁnition of PFS. The investigators
stated that one of the secondary outcomes was the “median time to
progression of disease”; however, they reported the PFS in the
results.
The trial by Hess et al19 evaluated 2 different dosing regimens of
temsirolimus (175/75 mg and 175/25 mg) against a control arm of
IC chemotherapy. The results led to the regulatory approval of the
175/75-mg dose in the European Union. Dreyling et al15 compared
ibrutinib to temsirolimus 175/75 mg. Some similarities were found
when comparing the baseline characteristics between the 2 trials;
thus, it would be feasible to compare the outcomes of these 2 trials.
What is striking is that across all outcome measures in the study by
Dreyling et al,15 temsirolimus outperformed those achieved in the
temsirolimus 175/75-mg arm of the trial by Hess et al,19 although
the duration of response reported was similar between the 2 trials.
Patients in the trial by Hess et al19 had received 2 to 7 previous
therapies (48% had received 4-7 previous treatments) compared
with  1 in the study by Dreyling et al15 (68% had received a
median of 1-2), which might account for the poorer performance of
temsirolimus, suggesting that earlier treatment is more effective.
The abstract presented by Rule et al34 at the 21st Congress of the
European Haematology Association in 2016 supports this idea. The
investigators reported survival outcomes for ibrutinib stratiﬁed by
the number of lines of previous therapy, which revealed that earlier
treatment is more effective. However, ibrutinib was signiﬁcantly
better than temsirolimus across all outcome measures in the trial by
Dreyling et al.15
The addition of rituximab to chemotherapy regimens for the
treatment of MCL has been established in a number of trials.
Included in the present review were the trials by Forstpointner
et al,16,17 which demonstrated that the addition of rituximab to the
combination of ﬂudarabine, cyclophosphamide, and mitoxantrone,
followed by rituximab maintenance for patients in remission
improved the response rates and OS. Maintenance rituximab
resulted in a greater proportion of patients experiencing ongoing
remission for > 2 years. The effect of rituximab on the outcome for
MCL patients inﬂuenced the decision to halt the trial by Furtado
et al18 early. The investigators had not incorporated rituximab into
the design of their study; however, during the recruitment period, it
had become part of standard care in the United Kingdom. Rummel
Madeliene Parrott et alet al20 had begun accrual for their trial in October 2003; however,
the investigators amended their protocol to allow patients who had
responded to either B-R or F-R chemotherapy to receive mainte-
nance rituximab after the report by Forstpointner et al.17 They
conducted a subgroup analysis of the total population, comparing
those patients who had received maintenance and those who had
not. The results conﬁrmed the effect that maintenance rituximab had
on PFS and OS in the relapsed/refractory setting after remission with
induction chemotherapy. Maintenance rituximab reduced the risk of
death or disease progression by 48% (PFS, P ¼ .01; OS, P ¼ .03).
The group of MCL patients who received maintenance rituximab
was too small for analysis. However, the trial reported by Rummel
et al35 at the 2016 annual meeting of the American Society of
Clinical Oncology, conducted in the ﬁrst-line setting, might give
some indication of what might be expected in MCL patients. No
statistically signiﬁcant difference in PFS was observed between pa-
tients receiving maintenance rituximab after B-R chemotherapy and
those not receiving maintenance rituximab (HR, 0.64; 95% CI,
0.36-1.14; P ¼ .130). They recruited 120 patients with newly
diagnosed MCL and concluded that after a median observation time
of 4.5 years, they were not able to demonstrate statistically signiﬁcant
evidence supporting the beneﬁt of rituximab maintenance after B-R.
Only 1 treatment, temsirolimus, appeared in > 1 trial; thus, the
results from each trial could not be quantitatively pooled by meta-
analysis. Although a limited network meta-analysis could theoreti-
cally have been performed of the data from Dreyling et al15 and
Hess et al19 because both trials included a temsirolimus arm, Hess
et al19 had included IC as a comparator. Thus, it was impossible to
evaluate the effectiveness of temsirolimus against particular drugs,
making the comparisons meaningless.
Because most patients with MCL are elderly, the tolerability of
treatment is an important factor when comparing different therapies
and should be evaluated on the per protocol population to accu-
rately reﬂect the adverse events in patients actually receiving the
drug. The grade  3 hematologic adverse event rates varied
considerably among the included trials. The rates of grade  3
hematologic toxicities were low with the combination of bend-
amustine and rituximab and the combination of ﬂudarabine and
rituximab in the trial by Rummel et al,20 with high-dose intensities
achieved in both arms of the trial. Ibrutinib was also well tolerated,
with low rates of myelosuppression despite a treatment exposure 3
times as long with ibrutinib than with temsirolimus 175/75 mg.15
Dose reductions were uncommon with ibrutinib, although 43%
of patients receiving temsirolimus 175/75 mg required a dose
reduction because of adverse events. Nearly one quarter of patients
treated with temsirolimus 175/75 mg in the trial by Hess et al19
discontinued treatment because of an adverse event. The results
from both of these trials suggest that temsirolimus at the approved
dose of 175/75 mg is poorly tolerated. In the trial by Forstpointner
et al,17 it was encouraging to note that rituximab maintenance did
not result in substantial additional treatment-associated hematologic
toxicities, with grade  3 adverse event rates very similar between
the maintenance and no maintenance arms.
Some of the novel agents identiﬁed in the present review are
being evaluated in the front-line setting, which will affect the choice
of agent when these patients subsequently develop a relapse. A UK
study36 evaluating ibrutinib and rituximab against a rituximab andchemotherapy combination in patients with newly diagnosed MCL
who are not eligible for intensive treatment is ongoing. The results
are expected in 2022. In addition, the SHINE trial (a study of the
Bruton tyrosine kinase inhibitor ibrutinib given in combination
with bendamustine and rituximab in patients with newly diagnosed
mantle cell lymphoma) is assessing the combination of ibrutinib
with B-R in patients with newly diagnosed MCL.37 A similar trial
evaluating the combination of the second-generation BTK inhibi-
tor, acalabrutinib, with B-R38 is ongoing, with the results due in
February 2021. If these prove to be successful, the paradigm for
relapsed or refractory disease will shift, and subsequent trials for
relapsed/refractory MCL will need to include patients who have
received previous ibrutinib or acalabrutinib treatment. A Spanish
trial39 is evaluating the combination of ibrutinib and rituximab in
patients with newly diagnosed indolent MCL. That trial is expected
to report results in January 2023. Several trials40-42 are evaluating
the role of lenalidomide in the ﬁrst-line setting, either combined
with chemotherapy or as maintenance after chemotherapy induc-
tion. The E1411 trial43 is evaluating the combination of bortezomib
with B-R as induction therapy, followed by rituximab with or
without lenalidomide as maintenance. The results are expected in
March 2019.
A number of new agents are being assessed for R/R MCL, either
as monotherapy or combined with established treatments, including
venetoclax (BCL-2 inhibitor), idelalisib, and buparlisib (PI3Kd in-
hibitors), the second-generation proteasome inhibitor carﬁlzomib,
daratumumab (an anti-CD38 monoclonal antibody), and geneti-
cally engineered chimeric antigen receptor T-cells (CAR T-cells). All
are currently being evaluated in single-arm trials.
As the landscape of treatment options for the management of R/
R MCL becomes more complicated, comparative studies will be
required to evaluate the relative advantages of 1 treatment over
another to ensure the optimal use of the available therapies. The
protocol only permitted the inclusion of RCTs, because that study
design provides the best evidence for the effectiveness of treatments.
Single-arm trials might provide additional information to clinicians
regarding the efﬁcacy of treatment options for this rare disease;
however, these are biased by the nature of their design. It is con-
cerning that only 1 of the ongoing studies is an RCT. Careful
consideration should be given to future trial designs to ensure that
meaningful evaluation of effectiveness of treatments can be
undertaken.
The challenging factor is that MCL remains a rare malignancy
with a small pool of patients from which to recruit to trials.
Collaboration between research groups and agreement of standards
for clinical trials is essential. In addition to this, using adaptive trial
designs to assess the relative merits of treatments could help in
addressing this challenge. Multi-arm, multistage trials have been
adopted in some therapeutic areas to allow the comparison of a
number of novel treatments compared simultaneously to a shared
control group.44 This can result in the provision of answers to
research questions more quickly and cost effectively with a smaller
number of patients and might be a suitable approach to adopt for
evaluating future treatments or combinations of treatments for
MCL patients.
The scarcity of high-quality RCTs of MCL highlights the difﬁ-
culty in evaluating the comparative efﬁcacy and safety of newClinical Lymphoma, Myeloma & Leukemia January 2018 - 23
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24 -therapies. Historical studies lack common comparators, exhibit
differences in inclusion criteria, and have small sample sizes.
Although prognostic indicators such as the simpliﬁed MCL inter-
national prognostic index score or blastoid variant were reported in
some of the studies, none of the trials reported outcomes according
to these important factors owing to the small numbers of patients in
these groups. The original protocol intended to undertake a sub-
group analysis for these prognostic indicators; however, owing to the
lack of data, such an analysis was not possible. Nevertheless, the
present review should help to guide treatment selection for elderly
patients with R/R MCL unsuitable for intensive chemotherapy or
transplantation.
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Supplemental Table 1 Medline (Ovid) Search Strategy
1. Lymphoma, Mantle-cell.mp. or *mantle cell lymphoma/
2. Lymphoma, non-Hodgkin.mp. or *nonhodgkin lymphoma/
3. B-cell.mp. or *B lymphocyte/
4. 1 or 2 or 3
5. Drug therapy.mp. or drug therapy/
6. Immunotherapy.mp. or immunotherapy/
7. Molecular targeted therapy.mp. or molecularly targeted therapy/
8. Biological therapy.mp. or biological therapy/
9. Combined modality therapy.mp. or multimodality cancer therapy/
10. Antineoplastic agents.mp. or antineoplastic agent/
11. Lenalidomide.mp. or lenalidomide/
12. Ibrutinib.mp. or ibrutinib/
13. Thalidomide.mp. or thalidomide/
14. Bortezomib.mp. or bortezomib/
15. Temsirolimus.mp. or temsirolimus/
16. Everolimus/ or everolimus.mp.
17. BTK inhibitor.mp. or Bruton tyrosine kinase inhibitor/
18. Proteasome inhibitor.mp. or proteasome inhibitor/ or ixazomib/
19. Immunomodulating agent/ or imid.mp.
20. Combination chemotherapy/ or chemotherapy/ or multimodal chemotherapy/ or cancer combination chemotherapy/ or chemotherapy.mp.
21. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
22. 4 and 21
23. Limit 22 to (randomized controlled trial and yr ¼ “1994-Current”)
Supplemental Table 2 Embase (Ovid) Search Strategy
1. Lymphoma, Mantle-cell.mp. or *mantle cell lymphoma/
2. Lymphoma, Non-Hodgkin.mp. or *nonhodgkin lymphoma/
3. B-cell.mp. or *B lymphocyte/
4. 1 or 2 or 3
5. Drug therapy.mp. or drug therapy/
6. Immunotherapy.mp. or immunotherapy/
7. Molecular targeted therapy.mp. or molecularly targeted therapy/
8. Biological therapy.mp. or biological therapy/
9. Combined modality therapy.mp. or multimodality cancer therapy/
10. Antineoplastic agents.mp. or antineoplastic agent/
11. Lenalidomide.mp. or lenalidomide/
12. Ibrutinib.mp. or ibrutinib/
13. Thalidomide.mp. or thalidomide/
14. Bortezomib.mp. or bortezomib/
15. Temsirolimus.mp. or temsirolimus/
16. Everolimus/ or everolimus.mp.
17. BTK inhibitor.mp. or Bruton tyrosine kinase inhibitor/
18. Proteasome inhibitor.mp. or proteasome inhibitor/ or ixazomib/
19. Immunomodulating agent/ or imid.mp.
20. Combination chemotherapy/ or chemotherapy/ or multimodal chemotherapy/ or cancer combination chemotherapy/ or chemotherapy.mp.
21. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
22. 4 and 21
23. Limit 22 to (randomized controlled trial and yr ¼ “1994-Current”)
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Supplemental Table 3 Quality Assessment of Included Trials of Mantle Cell Lymphoma
Investigator Criteria From Cochrane Collaboration Tool Assessment Notes
Dreying et al,15 2016 Was allocation sequence adequately generated? Yes Central randomization was used..based on
computer-generated randomization schedule;
randomization was balanced using randomly
permuted blocks
Was allocation adequately concealed? Yes Randomization scheme was implemented within
interactive web response system
Was participant and personnel knowledge of allocated
intervention prevented during the study?
Unclear Open label; patients and investigators were
unmasked to treatment assignment
Was knowledge of outcomes assessment adequately
prevented during the study?
Yes Outcome assessments were conducted by an
independent review committee using validated IWG
criteria
Were incomplete outcomes data adequately addressed? Yes All data were accounted for; analysis conducted
on ITT basis
Are reports of study free of suggestion of selective outcome
reporting?
Yes All prespeciﬁed outcomes reported
Was study apparently free of other problems that could
put it at a high risk of bias?
Yes Although protocol was amended to allow crossover to
investigational arm at progression, this would have
introduced bias against the investigational drug
Forstpointner et al,16
2004
Was allocation sequence adequately generated? Yes Central randomization procedure performed using
computer program and random permutated blocks
Was allocation adequately concealed? Yes Central allocation performed by telephone
Was participant and personnel knowledge of allocated
intervention prevented during the study?
Unclear Open label; patients and investigators were
unmasked to treatment assignment
Was knowledge of outcomes assessment adequately
prevented during the study?
Unclear Open label; responses were evaluated using validated
IWG criteria, although whether centrally or locally
reviewed was not stated
Were incomplete outcomes data adequately addressed? Yes Of 147 patients randomized to the trial, 128 were
evaluable; investigators accounted for remaining 19
patients
Are reports of the study free of suggestion of selective
outcome reporting?
Yes All prespeciﬁed outcomes were reported
Was the study apparently free of other problems that could
put it at a high risk of bias?
Yes Although the trial was stopped early, this was
prespeciﬁed and allowed for stopping when a level
of signiﬁcance was reached; treatment arms and
baseline characteristics were well balanced
Forstpointner et al,17
2006
Was allocation sequence adequately generated? Yes Central randomization procedure performed using
computer program and random permutated blocks
Was allocation adequately concealed? Yes Central allocation performed by telephone
Was participant and personnel knowledge of allocated
intervention prevented during the study?
Unclear Open label; patients and investigators were
unmasked to treatment assignment
Was knowledge of outcomes assessment adequately
prevented during the trial?
Unclear Responses were evaluated using validated IWG
criteria, although whether centrally or locally
reviewed not stated
Were incomplete outcomes data adequately addressed? Yes Investigators accounted for all patients and gave
reasons for those not included in the analysis
Are reports of the study free of suggestion of selective
outcomes reporting?
Yes All prespeciﬁed outcomes were reported
Was the study apparently free of other problems that could
put it at a high risk of bias?
Yes Analysis included 38 patients who received FCM as
induction instead of R-FCM. If any bias introduced it
would be against investigational arm
Furtado et al,18 2014 Was allocation sequence adequately generated? Unclear Method of sequence generation was not described;
insufﬁcient information to allow judgment
Was allocation adequately concealed? Unclear Method of concealment was not described;
insufﬁcient information to allow judgment
Was participant and personnel knowledge of allocated
intervention prevented during the study?
Unclear Open label; patients and investigators were
unmasked to treatment assignment
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Supplemental Table 3 Continued
Investigator Criteria From Cochrane Collaboration Tool Assessment Notes
Was knowledge of outcomes assessment adequately
prevented during the trial?
Unclear Responses were evaluated using validated IWG
criteria, although whether centrally or locally
reviewed not stated
Were incomplete outcomes data adequately addressed? Yes Of 46 patients included in the trial, 41 were
assessable; the investigators accounted for the
5 nonassessable patients and included them in the
analysis as nonresponders
Are reports of the study free of suggestion of selective
outcome reporting?
No The protocol prespeciﬁed the time to progression
and quality of life as secondary endpoints;
these were not reported
Was the study apparently free of other problems that
could put it at a high risk of bias?
No Imbalances were present in the baselines
characteristics, with more men in the CHOP arm
(91% vs. 65%) because interval from diagnosis
was shorter in the CHOP arm (19.7 vs. 24.7 mo)
and fewer patients had received previous rituximab
in the CHOP arm (17% vs. 43%)
Hess et al,19 2009 Was allocation sequence adequately generated? Unclear Method of sequence generation was not described;
insufﬁcient information to allow judgment
Was allocation adequately concealed? Unclear Method of concealment was not described;
insufﬁcient information to allow judgment
Was participant and personnel knowledge of allocated
intervention prevented during the study?
Unclear Open label; patients and investigators were
unmasked to treatment assignment
Was knowledge of outcomes assessment adequately
prevented during the trial?
Yes Outcomes assessments were conducted by an
independent review committee using validated IWG
criteria on an ITT basis
Were incomplete outcomes data adequately addressed? Yes No missing outcomes data
Are reports of the study free of suggestion of selective
outcomes reporting?
Yes All prespeciﬁed outcomes were reported
Was the study apparently free of other problems that
could put it at a high risk of bias?
Yes Baseline characteristics were generally well balanced;
imbalances were in favor of IC: fewer patients with
bone marrow involvement (39% vs. 54%), fewer
patients with blastoid variant (7% vs. 17%),
and more patients with previous bortezomib
therapy (31% vs. 19%)
Rummel et al,20 2016 Was allocation sequence adequately generated? Yes Randomization was conducted centrally according
to prespeciﬁed randomization lists with permuted
blocks of randomly variable block size
Was allocation adequately concealed? Yes Patients were randomized centrally under
concealment
Was participant and personnel knowledge of allocated
intervention prevented during the study?
Unclear Open label; patients and investigators were
unmasked to treatment assignment
Was knowledge of outcomes assessment adequately
prevented during the trial?
No Patients were assessed locally and not by an
independent review committee; response criteria
were not referenced in the study
Were incomplete outcomes data adequately addressed? Yes Analysis was conducted on a per protocol basis;
investigators accounted for all patients and gave
reasons for those not included in the analysis
Are reports of the study free of suggestion of selective
outcome reporting?
Yes All prespeciﬁed outcomes were reported
Was the study apparently free of other problems that
could put it at a high risk of bias?
Yes Baseline characteristics were similar between
the 2 groups
Trneny et al,21 2016 Was allocation sequence adequately generated? Yes Permuted-block randomization with block size of 6,
resulting in 50 blocks in each stratum
Was allocation adequately concealed? Yes A centralized interactive voice-response system was
used to allocate patients
Was participant and personnel knowledge of allocated
intervention prevented during the study?
Unclear Open label; patients and investigators were
unmasked to treatment assignment
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Investigator Criteria From Cochrane Collaboration Tool Assessment Notes
Was knowledge of outcomes assessment adequately
prevented during the trial?
Yes Outcomes assessments were conducted by an
independent review committee using validated IWG
criteria
Were incomplete outcomes data adequately addressed? Yes All data were accounted for; analysis conducted
on ITT basis
Are reports of the study free of suggestion of selective
outcome reporting?
Yes All prespeciﬁed outcomes were reported
Was the study apparently free of other problems that
could put it at a high risk of bias?
Yes Although protocol allowed crossover to investigational
arm at progression, this would have introduced bias
against the investigational drug
Abbreviations: CHOP ¼ cyclophosphamide, doxorubicin, vincristine, prednisolone; FCM ¼ ﬂudarabine, cyclophosphamide, mitoxantrone; IC ¼ investigator’s choice; ITT ¼ intent to treat; IWG ¼
International Working Group; R-FCM ¼ rituximab, ﬂudarabine, cyclophosphamide, mitoxantrone.
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Supplemental Table 4 Ongoing Trials of Relapsed/Refractory MCL
NCT Identiﬁer Study Design Treatment Line
Target Patient
Number
Primary
Outcome
Study
Completes
Combination trials
NCT02460276 A phase II trial of ibrutinib, lenalidomide and
rituximab for patients with relapsed/refractory
mantle cell lymphoma
1 Previous rituximab-
containing treatment
50 ORR based on PET
and CT
Mar 2019
NCT01880567 A phase II study of ibrutinib plus rituximab in
patients with relapsed/refractory mantle cell
lymphoma or elderly patients with newly
diagnosed mantle cell lymphoma
1 Previous treatment 100 ORR July 2019
NCT01737177 Bendamustine, lenalidomide and rituximab
(R2-B) combination as a second-line therapy
for ﬁrst relapsed-refractory mantle cell
lymphomas: a phase II study
1 previous treatment 42 CR based on IWG
2007 and
maintenance PFS
Jan 2017
NCT01996865 A phase 3B randomized study of lenalidomide
(CC-5013) plus rituximab maintenance therapy
followed by lenalidomide single-agent
maintenance versus rituximab in subjects with
relapsed/refractory follicular, marginal zone, or
mantle cell lymphoma
1 previous treatment 500 PFS based on IWG
1999
Mar 2023
NCT00980395 A phase II, open-label study of bortezomib
(Velcade), cladribine and rituximab (VCR) in
advanced, newly diagnosed and relapsed/
refractory mantle cell and indolent lymphomas
NS 39 PFS at 2 y Dec 2021
NCT02840539 A phase 2 trial to evaluate the efﬁcacy of
bortezomib, cytarabine, and dexamethasone in
patients with relapsed or refractory mantle cell
lymphoma
1-3 previous lines of
treatment
32 ORR Feb 2020
NCT02736617 A phase II study of obinutuzumab (GA-101) in
combination with ibrutinib (I) for the treatment
of relapsed mantle cell lymphoma
1 Previous treatment 20 Best ORR of CR/PR July 2021
NCT02471391 A phase 2 study of ABT-199 in combination
with ibrutinib in the treatment of patients
with relapsed or refractory mantle cell
lymphoma (AIM study)
1 Previous treatment 24 CR at 16 wk based
on IWG 2007
June 2018
NCT01796470 A phase 2 open-label study evaluating the
efﬁcacy, safety, tolerability, and
pharmacodynamics of GS-9973 (entospletinib)
in combination with idelalisib in subjects with
relapsed or refractory hematologic malignancies
NS 66 ORR Dec 2016
NCT00764517 Phase II study of vorinostat (SAHA), cladribine,
and rituximab (SCR) in mantle cell lymphoma,
chronic lymphocytic leukemia, and relapsed
B cell non-Hodgkin lymphoma
NS 66 ORR based on IWG
2007
March 2017
EudraCT: 2015-
004061-87
A phase 2 study to evaluate the efﬁcacy and
tolerability of IMGN529 in combination with
rituximab in patients with relapsed and/or
refractory diffuse large B-cell lymphoma and
other forms of non-Hodgkin lymphoma
1 Previous treatment 75 Safety and ORR NS
Monotherapy trials
NCT02601313 A phase 2 multicenter study evaluating the
efﬁcacy of KTE-C19 in subjects with relapsed/
refractory mantle cell lymphoma (R/R MCL)
(ZUMA-2)
5 Previous treatments,
which must have included
anthracycline or
bendamustine-containing
regimen, anti-CD20
mAb and ibrutinib
70 ORR based on IWG July 2018
NCT02042950 A phase II study of carﬁlzomib in the treatment
of relapsed/refractory mantle cell lymphoma
NS 60 ORR based on IWG
2007
Jul 2021
NCT02413489 An open label, phase 2 study to evaluate
efﬁcacy and safety of daratumumab in relapsed
or refractory mantle cell lymphoma, diffuse large
B-cell lymphoma, and follicular lymphoma
2 Previous lines of
treatment
210 ORR June 2017
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NCT Identiﬁer Study Design Treatment Line
Target Patient
Number
Primary
Outcome
Study
Completes
NCT02488512 Peptide receptor radionuclide therapy with
90Y-dotatoc in relapsed/refractory diffuse large
B cell (DLBCL) and mantle cell lymphomas
(MCL)
NS 35 ORR based on IWG Feb 2018
NCT02169180 A phase 2 study of the Bruton tyrosine kinase
(BTK) inhibitor ibrutinib in subjects with
relapsed or refractory mantle cell lymphoma
(MCL) in Japan
1 Previous treatment 16 ORR based on IWG
2007
Dec 2016
NCT02267915 An open multicenter phase II study of efﬁcacy
and toxicity of maintenance subcutaneous
rituximab after induction with rituximab in
patients with relapsed or refractory mantle-cell
lymphoma non-eligible for HSCT
1-2 Previous lines of
treatment
36 TTP Nov 2019
NCT01678417 A phase II study of 131I-rituximab for patients
with relapsed or refractory follicular or mantle
cell lymphoma
NS 29 ORR Jun 2017
NCT01693614 An open-label phase II study of BKM120 in
patients with relapsed and refractory diffuse
large B-cell lymphoma, mantle cell lymphoma
and follicular lymphoma
1 Previous treatment 72 ORR July 2017
NCT02213926 An open-label, phase 2 study of ACP-196 in
subjects with mantle cell lymphoma
NS 124 ORR Sept 2019
NCT02572453 Phase 2 study of AT13387 (onalespib) in ALKþ
ALCL, MCL, and BCL-6þ DLBCL
Previous multiagent
chemotherapy and
ibrutinib or other BTK
inhibitor
50 ORR, change in
protein levels of
ALK, BCL6, and
cyclin D1
Aug 2019
NCT01799889 A phase 2, open-label study evaluating the
efﬁcacy, safety, tolerability, and
pharmacodynamics of GS-9973 (entospletinib)
in subjects with relapsed or refractory
hematologic malignancies
NS 385 PFS May 2019
NCT02952508 An open-label, multicenter, phase 2 study
of CLR 131 in patients with relapsed or
refractory (R/R) select B-cell malignancies
1-2 Previous treatments 80 ORR Mar 2019
NCT01261247 A phase II study of the histone deacetylase
(HDAC) inhibitor LBH589 (panobinostat) in
patients with relapsed or refractory
non-Hodgkin lymphoma
1 Previous treatment 41 ORR Nov 2017
Abbreviations: ALCL ¼ anaplastic large cell lymphoma; CR ¼ complete response; CT ¼ computed tomography; DLBCL ¼ diffuse large B-cell lymphoma; HSCT ¼ hematopoietic stem cell
transplantation; IWG ¼ International Working Group; mAb ¼ monoclonal antibody; MCL ¼ mantle cell lymphoma; NS ¼ not stated; ORR ¼ overall response rate; PET ¼ positron emission to-
mography; PFS ¼ progression-free survival; PR ¼ partial response; R-GemOx ¼ rituximab, gemcitabine, oxaliplatin; R/R ¼ relapsed/refractory; TTP ¼ time to progression.
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